EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides Journal Article

   


Authors: Handkiewicz-Junak, D.; Poeppel, T. D.; Bodei, L.; Aktolun, C.; Ezziddin, S.; Giammarile, F.; Delgado-Bolton, R. C.; Gabriel, M.
Article Title: EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
Abstract: The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (89Sr), samarium-153 (153Sm) lexidronam (153Sm-EDTMP), and phosphorus-32 (32P) sodium phosphate; (b) performing the treatments; and ©) understanding and evaluating the treatment outcome and side effects. © 2018, The Author(s).
Keywords: efficacy; bone metastases; radionuclide therapy; beta-emitting radionuclides; phosphorus-32; samarium-153; strontium-89
Journal Title: European Journal of Nuclear Medicine and Molecular Imaging
Volume: 45
Issue: 5
ISSN: 1619-7070
Publisher: Springer  
Date Published: 2018-05-01
Start Page: 846
End Page: 859
Language: English
DOI: 10.1007/s00259-018-3947-x
PROVIDER: scopus
PUBMED: 29453701
PMCID: PMC5978928
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042139105&doi=10.1007%2fs00259-018-3947-x&partnerID=40&md5=2a9de1a11040dcc11094659c36ef5dae
Notes: Article -- Export Date: 2 April 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Lisa Bodei
    205 Bodei
Related MSK Work